Patents by Inventor Koji HAYASHIZAKI

Koji HAYASHIZAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10513561
    Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: December 24, 2019
    Assignees: National University Corporation Chiba University, Eisai R&D Management Co., Ltd.
    Inventors: Toshinori Nakayama, Motoko Kimura, Koji Hayashizaki, Toshifumi Hirayama, Jungo Kakuta, Yoshimasa Sakamoto, Ryu Gejima, Daisuke Tokita, Kenzo Muramoto, Toshio Imai
  • Publication number: 20190002543
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Applicant: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Publication number: 20190002588
    Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 3, 2019
    Inventors: Toshinori Nakayama, Motoko Kimura, Koji Hayashizaki, Toshifumi Hirayama, Jungo Kakuta, Yoshimasa Sakamoto, Ryu Gejima, Daisuke Tokita, Kenzo Muramoto, Toshio Imai
  • Patent number: 10100107
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: October 16, 2018
    Assignee: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Publication number: 20170334982
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 23, 2017
    Applicant: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Patent number: 9758574
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: September 12, 2017
    Assignee: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Publication number: 20160102139
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 14, 2016
    Inventors: Toshinori NAKAYAMA, Hiroyuki HOSOKAWA, Koji TOKOYODA, Koji HAYASHIZAKI, Akane SUZUKI